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Introduction: Biological features of non–small-cell lung carcinomas 
(NSCLCs) are important determinants for prognosis. In this study, 
differences in glucose metabolism between adeno- and squamous cell 
NSCLCs were quantified using the hypoxia and glycolysis-related 
markers glucose transporter 1 (GLUT1), carbonic anhydrase IX 
(CAIX), monocarboxylate transporter 1 (MCT1) and 4 (MCT4) vas-
culature, and 18-fluoro-2-deoxyglucose (18FDG)-uptake. Relevance 
of these markers for disease-free survival (DFS) was analyzed.
Methods: Patients with curatively resected stage I to II and resect-
able stage IIIA, cN0-1 adeno- or squamous cell NSCLC, of whom 
fresh-frozen lung resection biopsies and pretreatment 18FDG-positron 
emission tomography (PET) scans were available, were included in 
this study (n = 108). 18FDG-uptake was quantified by calculating total 
lesion glycolysis (TLG). Metabolic marker expression was measured 
by immunofluorescent staining (protein) and quantitative polymerase 
chain reaction (messenger ribonucleic acid [mRNA]). Patients were 
retrospectively evaluated for DFS.
Results: mRNA and protein expression of metabolic markers, with the 
exception of MCT4, and TLG were higher in squamous cell carcino-
mas than in adenocarcinomas, whereas adenocarcinomas were better 
vascularized. Adenocarcinomas had a worse DFS compared with squa-
mous cell carcinomas (p = 0.016) based on the potential to metastasize. 
High TLG was associated with a worse DFS only in adenocarcinomas.
Conclusion: Our findings suggest that the adenocarcinomas exhibit 
glycolysis under normoxic conditions, whereas squamous cell carci-
nomas are exposed to diffusion-limited hypoxia resulting in a very 
high anaerobic glycolytic rate. Although squamous cell carcinomas 
have a higher 18FDG-uptake, in general regarded as a poor prog-
nostic factor, adenocarcinomas have a higher metastatic potential 
and a worse DFS. These findings show that 18FDG-PET should be 
interpreted in relation to histology. This may improve the prognos-
tic potential of 18FDG-PET and may aid in exploiting 18FDG-PET in 
treatment strategies allied to histology.
Key Words: Non–small-cell lung cancer, Hypoxia-related markers, 
18-Fluoro-2-deoxyglucose positron emission tomography, Tumor 
microenvironment, Tumor glucose metabolism, Prognosis.
(J Thorac Oncol. 2014;9: 1485–1493)
Biological behavior of cancer cells is not only determined by the genotype of the tumor cells, but is also modified by 
the tumor microenvironment. For example, hypoxia, which is 
the result of an insufficient tumor microvasculature, plays a 
major role in cancer biology. Hypoxia is associated with more 
aggressive tumor behavior, impaired response to radiotherapy 
and chemotherapy, and worse clinical outcome.1 The metab-
olism of carcinomas is affected by hypoxia, as tumor cells 
switch to anaerobic glycolysis with the production of lactate 
under hypoxic conditions (Pasteur effect). However, in cancer 
cells, a high glycolytic rate is also observed in the presence of 
oxygen (Warburg effect). This glycolytic tumor metabolism 
is associated with selective growth advantage, tumor cell sur-
vival and treatment resistance.2–4 The higher rate of glucose 
consumption is one of the reasons why 18-fluoro-2-deoxyglu-
cose positron emission tomography (18FDG-PET) is useful as 
an imaging tool in solid tumors.2,5,6
The hypoxia-inducible factor-1 pathway plays a piv-
otal role in the cellular adaptation mechanisms to hypoxic 
conditions. The hypoxia-inducible factor-1 pathway controls 
expression of many endogenous hypoxia- and glycolysis-
related transporters and enzymes, such as glucose transporter 1 
(GLUT1), responsible for the cellular glucose uptake, carbonic 
anhydrase IX (CAIX), which prevents intracellular acidification, 
and monocarboxylate transporters (MCT) for the regulation of 
intracellular lactate level.1,7,8 Apart from hypoxia, several cancer-
associated mutations and cell signaling pathways are able to 
alter tumor metabolism, thereby inducing aerobic glycolysis.5,8
Several histological subtypes are categorized within the 
same disease entity “non–small-cell lung cancer” (NSCLC). 
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However, biological behavior and treatment-related outcome 
differ between histological subgroups of NSCLC.9,10 Former 
analysis of GLUT1 and MCT4 protein expression suggested 
differences in glucose metabolism between adeno- and squa-
mous cell carcinomas.11 This finding may have an important 
impact on the interpretation of 18FDG-PET scans of these two 
NSCLC histologies.
In the present study, we analyzed the tumor microen-
vironment and glucose metabolism of adeno- versus squa-
mous cell lung carcinomas by analyzing mRNA and protein 
levels of GLUT1, CAIX, MCT1, and MCT4, vasculature as 
well as 18FDG uptake in curatively resected NSCLC patients. 
Moreover, we determined the consequences of the differences 
in tumor glucose metabolism for survival.
PATIENTS AND METHODS
Patients
Patients who underwent a curative resection for stage I, 
II, and resectable stage IIIA, cN0-1 NSCLC at the Radboud 
University Medical Center between January 2002 and 
December 2008, who had fresh-frozen lung resection biop-
sies and pretreatment 18FDG-PET scans done, were included 
in this study. The study was performed according to the insti-
tutional ethical rules and regulations.
One hundred twenty-nine NSCLCs in 127 patients were 
identified.11 Patients who received neo-adjuvant treatment 
were excluded (n = 5). In five patients, both the PET-scan and 
fresh-frozen tissue were not available. In 11 tumors, other his-
tologies than adeno- or squamous cell carcinoma were found. 
These tumors were not evaluated. As shown in Figure 1, 108 
NSCLCs in 106 patients remained. In 103 patients with 105 
NSCLCs, a pretreatment diagnostic 18FDG-PET-scan was 
available for analysis. 18FDG-uptake of these carcinomas was 
correlated with clinicopathological parameters.
In the group of 108 NSCLCs, 25 fresh-frozen samples 
were not suitable for evaluation due to sampling error (absence 
of tumor tissue, presence of inflammatory tissue, or necrosis) 
and two biopsies could not be retrieved. This resulted in 81 
tumors of 79 patients available for immunofluorescent stain-
ing and quantitative polymerase chain reaction (qPCR) analy-
sis (Fig. 1). In this cohort of 81 tumors, immunofluorescent 
staining of GLUT1, CAIX, MCT1 and MCT4, and qPCR 
analysis of these markers were correlated with clinicopatho-
logical characteristics.
For treatment outcome analysis, three patients with 
incomplete anatomical resections based on unexpected stage 
IIIB/IV (tumor, node, metastasis [TNM] 7th edition) were 
excluded and one patient was lost to follow-up. Of the two 
patients with two synchronous primary NSCLCs, only the 
most advanced tumors were considered for survival analysis. 
Figure 1 summarizes the numbers of available patients for fol-
low-up analyses. Table 1 shows the clinicopathological char-
acteristics of adeno- versus squamous cell carcinomas that 
were available for “histology” follow-up analysis.
Immunofluorescent Staining for GLUT1, 
CAIX, MCT1, MCT4, and Vessels
Biopsies taken from lung cancer resection specimens 
were snap frozen in liquid nitrogen and stored at −80°C 
until further processing. Sections of 5 μm, mounted on 
poly-L-lysine coated slides, were stored at −80°C until 
immunofluorescent staining. Immunofluorescent staining 
of GLUT1, CAIX, MCT1, MCT4, and vasculature were 
performed as described before.11,12 One section per tumor 
was analyzed for every staining (region of interest). The 
evaluation of the GLUT1 and MCT4 immunofluorescent 
staining is based on the same patients as described in the 
study by Meijer et al.11
FIGUrE 1.  Flowchart of inclusion and exlusion 
criteria for correlation and follow-up analyses. 
Monocarboxylate transporter (MCT1) qPCR analysis 
failed in one tumor. NSCLC, non–small-cell lung 
carcinoma; FDG-PET, 18-fluoro-2-deoxyglucose 
positron emission tomography; qPCR, quantitative 
polymerase chain reaction.
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TAbLE 1.  Clinicopathological Characteristics of Adeno- vs. Squamous Cell Lung Carcinomas Available for Follow-Up Analysis
Characteristics
Adenocarcinomas, n (%), 
n = 55
Squamous Cell Carcinomas, 
n (%), n = 47
p Value Adenocarcinomas vs. 
Squamous Cell Carcinomas
Age (years)
  ≤65 26 (57) 20 (43) NS
  >65 29 (52) 27 (48)
Sex
  Male 29 (47) 33 (53) 0.05
  Female 26 (65) 14 (35)
Smoking statusa
  Current smoker 23 (51) 22 (49) NS
  Former smoker (>1 year) 29 (57) 22 (43)
  Never 3 (100) 0 (0)
Surgery
  Lobectomy 48 (59) 34 (41) NS
  Bilobectomy 3 (75) 1 (25)
  Pneumectomy 3 (23) 10 (77)
  Wedge resection 1 (33) 2 (67)
Tumor size (mm)
  <30 35 (67) 17 (33) 0.005
  ≥30 20 (40) 30 (60)
Differentiationb
  Well 8 (89) 1 (11) NS
  Moderate 23 (51) 22 (49)
  Poor 22 (48) 24 (52)
pT
  T1 23 (64) 13 (36) NS
  T2 24 (46) 28 (54)
  T3 6 (67) 3 (33)
  T4 2 (40) 3 (60)
pN
  N0 38 (59) 27 (41) NS
  N1 13 (48) 14 (52)
  N2 3 (37) 5 (63)
  Nxc 1 (50) 1 (50)
pTNM 7th edition
  Stage I 35 (63) 21 (37) 0.08
  Stage II 13 (42) 18 (58)
  Stage IIIA 7 (47) 8 (53)
Surgical margins
Free 48 (52) 44 (48) NS
Not free 6 (75) 2 (25)
Rxc 1 (50) 1 (50)
Adjuvant therapy
  Chemotherapy 9 (60) 6 (40) NS
  Radiotherapy 3 (37) 5 (63)
  No 43 (54) 36 (46)
aSmoking status is unknown in three patients with a squamous cell carcinoma.
bDifferentiation is unknown in two adenocarcinomas.
cAn incomplete mediastinal staging was performed due to the following reasons:
•   Only a wedge resection was performed based on comorbidity.
•   According to the TNM 6th edition, stage IV was diagnosed as a result of a tumor nodule in a different ipsilaterale lobe. According to the TNM 7th edition, however, this patient 
was classified as stage IIIA.
NS, not significant; TNM, tumor, node, metastasis.
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Fluorescence Microscope Image 
Acquisition and Analysis
Immunofluorescent image acquisition and analysis was 
described before.11 In short, the slides were scanned at 100× 
magnification using a high-resolution 12-bit charged-coupled 
device (CCD) camera (Coolsnap HQ; Roper Scientific Inc., 
Trenton, NJ) on a fluorescence microscope (Axioskop; Zeiss, 
Göttingen, Germany). This resulted in gray scale images, 
which were converted to binary images for further analysis. 
The tumor area was marked on the stained sections. Marker 
fractions were defined as the tumor area positive for the 
marker (binary images), divided by the total tumor area.
reverse-Transcriptase-PCr
Total RNA was isolated with the Norgen’s Total RNA 
purification kit (Norgen Biotek Corp., Thorold, Ontario, 
Canada), and reversed transcribed using Gibco SuperScript 
II Reverse Transcriptase (Life technologies, Carlsbad, CA). 
qPCR was performed with specific primers for GLUT1 (Forward 
[FW]: 5’-GAGCATCATCTTCATCCC-3’, Reverse [RV]: 
5’-TCTTTAGCACACTCTTGG-3’), CAIX (FW: 5’-GAGGC 
CTGGCCGTGTTG-3’), RV: 5’-CTGAGCCTTCCTCAGC 
GATT-3’), MCT1 (FW: 5’-TCTGTGTCTATGCGGGATT 
CTT-3’, RV: 5’-TTGAGCCGACCTAAAAGTGGT-3’), and 
MCT4 (FW: 5’-GTTGGGTTTGGCACTCAACT-3’, RV: 
5’-GAAGACAGGGCTACCTGC-3’) on a CFX96 real-time 
PCR detection system (Bio-Rad Laboratories Inc., Richmond, 
CA) using SYBR Green. The levels are expressed as ratios 
of hypoxanthine ribosyltransferase (HPRT).13
18FDG-PET
Prior to 18FDG injection, patients fasted for 6 hours or 
more. PET-scans were performed 60 minutes after intravenous 
injection of approximately 250 MBq 18FDG (Covidien, Petten, 
The Netherlands) and 10 mg furosemide. PET-scans were 
acquired on an emission computed axial tomograph (ECAT)-
EXACT full ring PET-scanner (Siemens/CTI, Knoxville, TN) 
until September 2005, using three-dimensional emission of 10 
minutes per bed position and germanium-68 2 minutes per bed 
position trasmission scans for attenuation correction. The PET 
scans were iteratively reconstructed using two iterations and 
eight subsets. From September 2005 onwards, the PET scans 
were acquired on a PET/computed tomography (CT) scanner 
(Biograph Duo; Siemens Medical Solutions USA, Inc.) using 
three-dimensional emissions of 4 minutes per bed position. A 
low-dose CT scan for localization and attenuation-correction 
purposes was acquired. Scanning parameters included 40 
mA∙s (50 mA∙s for patient weight >100 kg and 60 mA∙s for 
>120 kg), 130 kV, 5-mm slice collimation, 0.8-second rota-
tion time, and pitch of 1.5, reconstructed to 3-mm slices for 
smooth coronal representation. Both PET-scanners were cross 
calibrated with the dose calibrator in which the administered 
activity was measured. A detailed description of the cross 
calibration is described in Supplementary data (Supplemental 
Digital Content, http://links.lww.com/JTO/A662).
Volumes of interest were drawn using a 40% fixed 
threshold isocontour value.14,15 Subsequently, the metabolic 
tumor volumes and the mean standardized uptake value (SUV 
mean) were calculated. TLG was calculated by multiplying 
tumor volume (cm3) and SUV mean.
Clinical Follow-Up
The patients were retrospectively evaluated for DFS in 
November 2013, which was calculated from the date of sur-
gery to the date of lung cancer related relapse. The follow-
up was according to the national guidelines and consisted of 
clinical and radiological (at least chest radiograph) routine 
follow-up every 3 months in the first year and every 6 months 
from the second year or earlier if patients were symptomatic. 
The follow-up was censored at the time of diagnosis of a sec-
ond metachronous primary lung cancer and death not related 
to NSCLC.
Statistical Analysis
Statistical analyses were performed using SPSS 18.0 
statistical software (SPSS Inc., Chicago, IL). The Pearson 
Chi-Square test and Spearman correlation were used to deter-
mine associations between histology and the other clinico-
pathological parameters. Differences between histological 
subtypes were measured by the means of the Mann–Whitney 
U test or the Independent-Samples t test where appropriate. 
Survival analyses were done with the Cox Regression and 
Kaplan–Meier method. DFS analyses were performed for 
adeno- and squamous cell carcinomas separately. For the vari-
ous variables (marker fraction, mRNA level, TLG), the study 
population was dichotomized into low and high based on the 
median values. Due to the small number of events and con-
sequently low statistical power, no further subgroup analysis 
was performed within the squamous cell carcinomas. The 
number of events precluded multivariate analyses.16 A p value 
less than 0.05 was considered statistically significant.
rESULTS
Metabolic Marker Expression in NSCLC
GLUT1, CAIX, MCT1, and MCT4 protein expression 
was confined to the cell membrane. Examples of tumors after 
immunofluorescent staining for these markers and vascula-
ture are shown in Figure 2. mRNA results of GLUT1, CAIX, 
MCT1, and MCT4 are shown in Table 2.
In the total cohort of 81 samples available for tissue cor-
relation analysis (Fig. 1), GLUT1, CAIX, MCT1, and MCT4 
protein expression correlated significantly with mRNA data 
(r [seconds] = 0.51, 0.73, 0.43, and 0.49 respectively; p ≤ 0.001).
Tumor Microenvironment and Glucose 
Metabolism in relation to Histology
Protein and mRNA expression of GLUT1, CAIX, and 
MCT1 were significantly higher in squamous cell carcinomas 
relative to adenocarcinomas (Fig. 3A–C and Table 2). CAIX 
protein expression was present in 83% of the squamous cell car-
cinomas, whereas only 47% of the adenocarcinomas expressed 
CAIX (p = 0.001). MCT1 protein expression was detectable in 
42% of the squamous cell carcinomas compared to only 7% of 
adenocarcinomas (p < 0.001). MCT4 expression did not differ 
between adeno- and squamous cell NSCLC (Fig. 3D).
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Other prominent differences were a significantly higher 
vascular density in adenocarcinomas (p < 0.001) (Fig. 3E), 
larger tumor size in squamous cell carcinomas (Table 1), and 
a significant higher TLG (p = 0.002) in squamous cell carci-
nomas (Fig. 3F–H).
Disease-Free Survival in Adeno- versus 
Squamous Cell Carcinomas
Adeno- versus squamous cell carcinomas.
In our cohort of NSCLC patients, DFS was worse for 
patients with adenocarcinomas relative to squamous cell car-
cinomas based on the potential of adenocarcinomas to metas-
tasize (hazard ratio [HR], 2.53; 95% CI, 1.1–5.1; p = 0.027) 
(Fig. 4A). Of the adenocarcinomas, 7% developed a local 
relapse, 13% a regional relapse, and 36% distant metastases 
during follow-up, whereas 4% of the squamous cell carci-
nomas encountered a local relapse, 6% a regional relapse, 
and only 15% developed distant metastases. This resulted in 
a 5-year DFS of 60% for adenocarcinomas versus 82% for 
squamous cell carcinomas. Clinicopathological variables were 
equally distributed among these histologies, with the excep-
tion of tumor size and sex (Table 1).
DFS according to glucose metabolism.
High TLG in adenocarcinomas identified patients with 
a significant worse DFS in this histology (cut-off value set 
at median [11.1]; HR, 3.36; 95% CI, 1.28–8.80; p = 0.008) 
(Fig. 4B). Adenocarcinomas with low TLG have a 5-year 
DFS of 78% versus 40% for adenocarcinomas with high 
TLG. High TLG in adenocarcinomas correlated with larger 
tumor size (p < 0.001) and worse pTNM stage (p = 0.005).
Despite the fact that squamous cell carcinomas have a 
high 18FDG-uptake (Fig. 3F–H), in general regarded as a poor 
prognostic factor, this histology had a better DFS than adeno-
carcinomas. Furthermore, the subset of adenocarcinomas with 
high TLG had a worse DFS compared with all squamous cell 
carcinomas, which have comparable TLG values and clinico-
pathological characteristics as this subset of adenocarcinomas 
with high TLG (HR, 4.05; 95% CI, 1.9–12.04; p < 0.001). 
DFS of all squamous cell carcinomas versus adenocarcinomas 
with low TLG did not differ (Fig. 4B).
DISCUSSION
In this study, we analyzed the tumor microenvironment 
and tumor glucose metabolism of adeno- versus squamous 
cell lung carcinomas using the expression of hypoxia and gly-
colysis-related markers, vascular density, and 18FDG-uptake 
in curatively resected stage I to IIIA NSCLC. Despite the fact 
that adeno- and squamous cell carcinomas are categorized 
within the same disease entity of “NSCLC,” we found remark-
able differences between these histological types.
Tumor Microenvironment and 
Glucose Metabolism of Adeno- versus 
Squamous Cell Lung Carcinomas
Expression of the hypoxia- and glycolysis-related mark-
ers GLUT1, CAIX and MCT1 on both mRNA and protein 
level, and 18FDG-uptake were stronger in squamous cell car-
cinomas compared with adenocarcinomas. Other studies also 
showed a higher expression of GLUT1 and CAIX protein, 
FIGUrE 2.  Immunofluorescent images of squamous cell 
non–small-cell lung carcinomas showing GLUT1 (A), CAIX 
(B), MCT1 (C), and MCT4 (D) protein expression. GLUT1, 
CAIX, and MCT4 expressions show a diffusion-limited pat-
tern, whereas MCT1 is up-regulated at the proximity of 
vessels. Red, GLUT1, CAIX, MCT1, or MCT4; green, vessels; 
magnification 100×; scale bars represent 100 μm. GLUT1, 
glucose transporter 1; MCT1, monocarboxylate transporter 
1; CAIX, carbonic anhydrase IX; MCT4, monocarboxylate 
transporter 4.
TAbLE 2.  Expression of GLUT1, CAIX, MCT1, and MCT4 mRNA within Adeno- vs. Squamous Cell NSCLC
Metabolic Marker
Adenocarcinomas, 
n = 45
Squamous Cell Carcinomas, 
n = 36
p Value
Adenocarcinoma vs. Squamous 
Cell Carcinoma
GLUT1: HPRT 2.13 (0.00–99.73) 4.60 (0.57–49.52) 0.003
CAIX: HPRT 0.03 (0.00–1.34) 0.11 (0.00–1.59) 0.017
MCT1: HPRT 0.07 (0.00–0.56) 0.23 (0.07–2.27)a <0.001
MCT4: HPRT 0.13 (0.01–1.87) 0.08 (0.02–0.71) NS
Messenger ribonucleic acid levels are expressed as ratios of HPRT. Values represent median (range).
aQuantitative polymerase chain reaction failed in one case.
GLUT1, glucose transporter 1; HPRT, hypoxanthine ribosyltransferase; CAIX, carbonic anhydrase IX; MCT, monocarboxylate transporter; NSCLC, non–small-cell lung carcinoma.
1490 Copyright © 2014 by the International Association for the Study of Lung Cancer
Schuurbiers et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 10, October 2014
and higher 18FDG-uptake in squamous cell carcinomas.17–24  
The lower vascular density in squamous cell carcinomas sug-
gests that tumor blood perfusion is less optimal in these tumors, 
which could lead to areas of diffusion-limited hypoxia and 
subsequent upregulation of the metabolic markers. Earlier, 
we demonstrated the diffusion-limited pattern of GLUT1 
and MCT4 protein expression in squamous cell NSCLCs.11 
Hypoxia is an important cause of tumor necrosis, which is a 
known feature of squamous cell carcinomas.25,26 Fan et al.27 
also showed that the microvessel density is higher in adeno-
carcinomas. Furthermore, flow extraction product on dynamic 
contrast-enhanced CT, which represents both blood flow and 
FIGUrE 3.  Tumor microenvironment and tumor glucose metabolism of adeno- versus squamous cell carcinomas. A–D, 
Squamous cell carcinomas demonstrate higher expression of the hypoxia- and glycolysis-related markers on both protein and 
messenger ribonucleic acid (mRNA) level, with the exception of MCT4 compared with adenocarcinomas. E, Vascular density 
(number of vessels per squared millimeter) is significantly higher in adenocarcinomas. F–H, Squamous cell carcinomas are better 
visualized on 18-fluoro-2-deoxyglucose positron emission tomography as measured by TLG (mean standardized uptake value 
× metabolic tumor volume [cm3]) (F). G, Demonstrates a pT1aN0M0 adenocarcinoma with a tumor size of 2 cm. TLG is 8.6. 
H, Shows a pT2aN0M0 squamous cell carcinoma. Tumor size is 4.5 cm and TLG is 263.6. mRNA levels are expressed as ratios 
of hypoxanthine ribosyltransferase (HPRT). The Boxes represent lower quartile, median value and upper quartile, and whiskers 
represent minimum and maximum value. GLUT1, glucose transporter 1; CAIX, carbonic anhydrase IX; MCT1, monocarboxylate 
transporter 1; MCT4, monocarboxylate transporter 4; TLG, total lesion glycolysis.
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vascular permeability, is significantly higher in adenocarcino-
mas than in squamous cell carcinomas, which was however not 
confirmed by others.23,28 López-Ríos et al. examined the ratio 
of β-F1-ATPase, an adenosine triphosphate (ATP)-producing 
enzyme of the mitochondrial oxidative phosphorylation, and 
glyceraldehyde-3-phosphate dehydrogenase, a glycolytic 
enzyme. Adenocarcinomas demonstrated a higher ratio than 
squamous cell carcinomas, indicating a higher rate of oxidative 
phosphorylation in adenocarcinomas and a higher glycolytic 
rate in squamous cell carcinomas.29
The intermediates of glycolysis can be utilized in 
the pentose phosphate pathway to synthetize precursors 
of nucleotides and amino acids, which are macromole-
cules required for tumor cell growth and proliferation.30,31 
Proliferation rate, as assessed by Ki67 and MCM7 expres-
sion, is higher in NSCLCs with higher SUVmax,24,28 in 
CAIX-positive areas of NSCLCs,21 and in squamous cell 
lung carcinomas.24,32
In summary, regarding the tumor microenvironment 
and glucose metabolism of NSCLCs, our results indicate that 
squamous cell carcinomas might be exposed to diffusion-
limited hypoxia, resulting in an anaerobic glycolytic tumor 
metabolism. This metabolism may contribute to a high prolif-
eration rate through the pentose phosphate pathway. In adeno-
carcinomas, expression of the hypoxia- and glycolysis-related 
markers and 18FDG-uptake was lower, accompanied by high 
vascular density. This suggests that adenocarcinomas produce 
pyruvate and lactate under normoxic conditions and have a 
higher rate of oxidative phosphorylation.11
Survival of Adeno- versus Squamous Cell 
NSCLCs with respect to Glucose Metabolism
A retrospective multivariate analysis of prognostic fac-
tors analyzed 12,428 stage I to IV NSCLC patients. In this 
multivariate analysis, squamous cell carcinoma histology 
was identified as an independent favorable prognostic factor, 
which is in agreement with our results.33
Within the adenocarcinoma subgroup of our cohort, 
high glucose dependency, measured by high TLG, correlated 
with positive lymph nodes and more advanced stage at diag-
nosis (data not shown), and a significant worse DFS in this 
histology. The prognostic significance of 18FDG-PET has been 
shown in NSCLC patients treated with surgery, chemo- or 
radiotherapy.34,35 However, despite the fact that the squamous 
cell carcinomas have a high TLG, in general regarded as a 
poor prognostic factor, this histology had a significant bet-
ter prognosis in our cohort than a subset of adenocarcinomas 
with comparable high TLG. DFS did not differ between squa-
mous cell carcinomas and adenocarcinomas with low TLG. 
Therefore, our results indicate that the meaning of 18FDG 
accumulation differs among NSCLC histologies with respect 
to understanding tumor glucose metabolism and the estima-
tion of prognosis.
The question remains why the squamous cell car-
cinomas with their high rate of glucose metabolism have a 
favorable prognosis compared with the adenocarcinomas. 
Adenocarcinomas are known to have a high metastatic poten-
tial, whereas progressive localized disease is more often found 
for squamous cell histology.25 Several cellular processes, such 
as epithelial-mesenchymal transition (EMT), cell motility and 
invasion, are required for the formation of distant metastases. 
Adenocarcinomas may use their energy metabolism to sup-
port these processes. For example, high MCT4 expression 
and resulting high lactate levels at the proximity of vessels 
in adenocarcinomas may create a tumor microenvironment 
favorable for tumor cell migration.4,11 Expression of both 
FoxQ1, which has a key role in regulating EMT, and vimentin, 
a mesenchymal marker, were significantly higher in adenocar-
cinomas than in squamous cell carcinomas, which was how-
ever not confirmed by others.36–38 Signalling through the MET 
pathway promotes the development of an invasive phenotype. 
c-MET and phospho-MET proteins are higher expressed in 
adenocarcinomas than in squamous cell carcinomas.39 Future 
studies are warranted to explore the metastatic potential of 
adeno- versus squamous cell NSCLCs and its relation to 
tumor metabolism.
Exploiting Differences in biological 
behavior between Adeno- and Squamous 
Cell NSCLCs in Treatment Strategies
NSCLC histology is predictive for treatment efficacy and 
clinical outcome.9 For example, a consistent link between his-
tology and treatment outcome was established for epidermal 
growth factor receptor tyrosine kinase inhibitors and peme-
trexed.9,40 Differences in metabolism between histologies may 
also be exploited in treatment strategies. For example, apart 
from hypoxia, a high rate of glucose metabolism is involved 
in resistance to radiotherapy.4 Therefore, glycolysis inhibitors 
FIGUrE 4.  Disease-free survival according to histological 
subtype (A) and TLG in adenocarcinomas (B). Cut-off value of 
TLG is set at median (11.1). TLG, total lesion glycolysis.
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in combination with chemoradiotherapy, or a radiation boost 
directed toward regions with high 18FDG-uptake may be used 
to enhance radiotherapy efficacy.11,41,42
Locoregional control and survival remains poor in 
irresectable stage III NSCLC, despite the use of concurrent 
instead of sequential chemoradiation.43 As we demonstrated 
that squamous cell carcinomas have a very high glycolytic rate, 
irresectable stage III squamous cell carcinomas might benefit 
from glycolysis targeting in combination with chemoradiation 
to improve locoregional control. The subset of adenocarci-
nomas with high glucose consumption and a worse survival 
may also benefit from glycolysis targeting combined with 
chemotherapy and/or radiotherapy. To exploit metabolism 
in these combined treatment modalities, it has to be exam-
ined whether our results, that is, the difference in metabolic 
behavior between resectable stage I to IIIA adenocarcinomas 
and squamous cell carcinomas, can be translated to irresect-
able stage III NSCLC. Furthermore, to assess treatment-by-
histology interactions large studies are needed, which may aid 
in maximizing survival in NSCLC patients by refinement of 
therapy allied to histology.
CONCLUSION
In the present study, we analyzed differences in the 
tumor microenvironment and glucose metabolism of adeno- 
versus squamous cell NSCLCs, and the consequences of 
these differences for prognosis. Squamous cell carcinomas 
have a higher glycotic rate on both the mRNA and protein 
level, are better visualized on 18FDG-PET, and have a worse 
vascularization compared with adenocarcinomas. This sug-
gests that squamous cell carcinomas demonstrate glycoly-
sis mainly under hypoxic conditions. Despite the fact that 
adenocarcinomas have a lower 18FDG-uptake, generally 
believed to be a favorable prognostic factor, relative to squa-
mous cell carcinomas, adenocarcinomas have a higher meta-
static potential and a worse DFS. These findings show that 
18FDG-PET should be interpreted in relation to histology. 
This may improve the prognostic potential of 18FDG-PET 
and may aid in exploiting 18FDG-PET in treatment strategies 
allied to histology.
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